Evidence map›Paper›PMID 34887660›Full record

ArticleInternational journal of nanomedicine2021

Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin-Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery.

Bing Xu, Mengmeng Yan, Fei Zhou, Desheng Cai, Wenbo Guo, Xiaohui Jia, Runping Liu, Tao Ma, Tong Li, Feng Gao and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Bing XuSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Mengmeng YanSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Fei ZhouSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Desheng CaiSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Wenbo GuoSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Xiaohui JiaSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Runping LiuSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Tao MaSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Tong LiSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Feng GaoSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Penglong WangSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Haimin LeiSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China.
Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical utility of camptothecin (CPT) is restricted by poor aqueous solubility, high lipophilicity, active lactone ring instability, and off-targeted toxicities. We report here a prostate-specific membrane antigen (PSMA) and esterase dual responsive self-assembled nanoparticles (CPT-WT-H NPs) for highly efficient CPT delivery and effective cancer therapy. METHODS AND

resultsIn this study, smart self-assembled nanoparticles CPT-WT-H NPs were elaborately designed and synthesized by combing hydrophobic CPT with hydrophilic PSMA-responsive penta-peptide via a cleavable ester bond. This dual responsive nanoparticle with negatively charged surface first respond to the extracellular PSMA and then to the intracellular esterase, achieving a programmable release of CPT at the tumor site and producing the byproducts of biocompatible glutamic acid and aspartic acid. Our data demonstrated that CPT-WT-H NPs exhibited greatly improved water solubility and stability. Results from MTT and flow cytometry showed CPT-WT-H NPs exhibited significantly higher cytotoxicity as well as apoptosis-inducing activity against PSMA-expressing LNCaP-FGC cells than the non-PSMA-expressing cancer cells, showing excellent cytotoxic selectivity. Moreover, the unique nanostructure provided the efficient transportation of CPT to tumor site, which resulted in the effective inhibition of tumor growth and low systemic toxicity in vivo.

conclusionCPT-WT-H NPs exhibited excellent in vitro PSMA-response ability and in vivo antitumor activity and safety, holding the promise to become a new and potent anticancer drug. The current research presents a promising strategy for efficient drug delivery.

Indexed as

Antineoplastic AgentsNanoparticlesProdrugsCamptothecinCell Line, TumorDrug Delivery SystemsDrug LiberationEsterasesHumansMaleOligopeptidesProstateAntineoplastic AgentsCamptothecinEsterasesOligopeptidesProdrugsCPT prodrugdual responsiveprostate-specific membrane antigenself-assemblysequential drug release

Identifiers

PMID34887660
PMCPMC8650835
OpenAlexW3216661066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.